Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones

NASHVILLE--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it has commenced an underwritten registered public offering of $100 million aggregate principal amount of senior notes due 2027, subject to market and certain other conditions. Harrow expects to grant the underwriters a 30‑day option to purchase an additiona